All News

audience learn

ACR20 – Day 1 Report

Jack Cush, MD

Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:

Read Article
Covid lung pneumonia corona (keep)

Clinical Trial Boom or Bust in Severe COVID-19

Jack Cush, MD

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.



Remdesivir

Read Article
podcast logo

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Jack Cush, MD

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
URI.infection.COrona.jpg

COVID Transmission from Young to Old

Jack Cush, MD

The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.

Read Article
DVT.PE_.Blood_.jpg

Tofacitinib and Thromboembolic Risk

Jack Cush, MD

Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (10 m

Read Article
Most ignore pharmacists annoying faxes re safety of QT interval with #hydroxycholoroquine likely the right thing to do! @RheumNow #ACR2020 @CRASCRRheum abstr#431. https://t.co/pXBIDOV2MP
Janet Pope Janetbirdope ( View Tweet)
In the search for biomarkers in PsA, interesting study showing absolute lymphocyte count is negatively correlated with cardiovascular disease risk score and red cell distribution width and increases with TNF-Inhibitor Therapy @rheumnow #ACR20 Abstr#878

Dr. Antoni Chan synovialjoints ( View Tweet)

Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z

sheila RHEUMarampa ( View Tweet)
Lung disease in primary #SjogrensSyndrome is common; both conditions were diagnosed at the same time in 43% of patients, found an #ACR20 study from @joannamarco @GGRheumdoc + @UW @uofcincy colleagues. “Close monitoring is warranted” to make sure lung function is not declining. https://t.co/MpA0Rq2uVR
CreakyJoints.org CreakyJoints ( View Tweet)
UK Biobank data: RA is associated with not just restrictive but also *obstructive* patterns on spirometry/PFTs (independent of smoking). Consistent observation; direction of causality? The lung in RA continues to fascinate. Prisco @jeffsparks et al #ACR20 ABST0491 @RheumNow https://t.co/LcjtAefnVF
David Liew drdavidliew ( View Tweet)
ILD in SSc has grave consequences. Abstr#393 Claims database in Ontario shows relevant Scleroderma ILD occurred in 17% of >3000 pts with nearly double the mortality #ACR20 @RheumNow @CRASCRRheum #bestinclass https://t.co/K3UXvuxBcp
Janet Pope Janetbirdope ( View Tweet)
#ACR20 Abstr#0433 #PlenaryACR Georgia SLE registry 336 pts ⬆️stroke/isch heart dz with: 👉3X stroke risk and 24X IHD risk for black pts 👉predictors stroke: black race, DLE, renal dz 👉predictors IHD: age>65, black race, neuro & immuno d/o (e.g, APAs) @RheumNow https://t.co/u6Ky7r0FYF
k dao KDAO2011 ( View Tweet)
Plenary session 1 no#2F011 #ACR20 @rheumnow Black #SLE patients have a 3 fold higher stroke and 24 fold higher Ishemic Heart Disease risk! https://t.co/AYtiXk7pDa
Bella Mehta bella_mehta ( View Tweet)
Dr Fernandez-Diaz on abatacept in RA-ILD in 263 patients. Abatacept appears safe and effective. Equivalent to RTX. Good option as s/c admin @rheumnow #ACR20 Abstr#0233 #ACRbest https://t.co/LfjqZpnGCh
Richard Conway RichardPAConway ( View Tweet)
When prescribing hydroxychloroquine for RA, SLE, or other rheumatic diseases, do you routinely order an EKG (either before or during)? #ACR20 @RheumNow

David Liew drdavidliew ( View Tweet)

Using #MachineLearning, multimorbidity patterns predominant for #rheumatoid arthritis: cardiometabolic, cardiopulmonary & #Mentalhealth/pain disorders. Patterns similar to non-RA pts but prevalence higher in RA pts. @RheumNow #ACR20 abstr#0179 https://t.co/zfCxzKquDV
sheila RHEUMarampa ( View Tweet)
What do you do with pharmacist drug alert for antimalarial cardiac safety &/or drug interactions @RheumNow #ACR2020 @CRASCRRheum

Janet Pope Janetbirdope ( View Tweet)

Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) https://t.co/LGERY3mpe5 #febuxostat #allopurinol #CVS some cardiac reassurance feboxustat

Links:

Peter Nash drpnash ( View Tweet)

Swedish population studied CV risk, studied gout. Among 22,057, 910 (4.1%) developed incident gout by 27.5 yrs w/ 5 Clusters: C1 no/few comorb; C2 had CKD; C3 CV dz; C4 obesity, dyslipidemia; C5 DM, HTN, diuretics. 86% of incident gout came from C1 & C4 https://t.co/TeMdXx5qU1

Links:

Dr. John Cush RheumNow ( View Tweet)

EUSTAR study of ILD in systemic sclerosis: 826 pts with SSc-ILD finds 27% with progressive ILD (mod-severe FVC decline >5-10%) over 12 mos. Predictive factors for FVC decline over 5 yrs were male sex, higher mRSS skin score and reflux/dysphagia symptoms. https://t.co/lLd2FrMIkx

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×